ROOTSTOWN, Ohio, January 06, 2026--(BUSINESS WIRE)--As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is ...
BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, ...
Epidermolysis bullosa is a rare skin condition that’s usually inherited. It makes the skin incredibly thin and brittle. People born with this condition are often called “butterfly children” because ...
Epidermolysis Bullosa, also colloquially known as butterfly skin disease, a rare genetic condition that makes your skin very fragile. While the symptoms usually show up in babies or young children, ...
As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...
As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results